Third, the study was performed in two Centers belonging to the same group, thus allowing a more uniform clinical management of patients in terms of indication for other medical treatments and ventilatory support. was comparable between groups (27% with tocilizumab vs. 38%) and at multivariable analysis risk of death was not Rabbit polyclonal to AADACL2 significantly influenced by tocilizumab (hazard ratio 0.61, 95% confidence interval 0.33C1.15), while being associated with the use at baseline of non invasive mechanical or invasive ventilation, and the presence of comorbidities. Among secondary outcomes, tocilizumab was JI051 associated with a lower probability of requiring invasive ventilation (hazard ratio 0.36, 95% confidence interval 0.16C0.83; P?=?0.017) but not with the risk of thrombosis, bleeding, or infections. The use of intravenous tocilizumab was not associated with changes in 30-day mortality in patients with COVID-19 severe respiratory impairment. Among the secondary outcomes there was less use of invasive ventilation in the tocilizumab group. analysis to compare death occurring between days 6 and 30 and observed a significant difference between groups, with a HR of 0.41 associated with tocilizumab (95% CI 0.17C0.96, P?=?0.039). Open in a separate windows Fig. 1 Survival curves in patients with COVID-19 receiving tocilizumab (red) and those not receiving the drug (blue) are represented using Kaplan-Meier estimates. Data are censored at 30 days. Of note, after observing the CRP decrease by day 5 and the lack of differences between the two groups in the first 5 days of observation, we performed a post-hoc analysis which provided a hazard ratio for death occurring between days 6 and 30 of 0.41 (95% CI 0.17C0.96, P?=?0.039) for TCZ vs controls. (For interpretation of the recommendations to colour in this physique legend, the reader is referred to the Web version of this article.) Clinically relevant JI051 secondary outcomes, including the need for invasive ventilation, thrombotic events, major bleeding, and bacterial or fungal infections are illustrated in Table 4 in terms of both incidence over 30 days in the two groups and HR (95% CI) for tocilizumab vs. controls. The use of tocilizumab was associated with a lower risk to require invasive ventilation in patients who were not receiving this respiratory support at baseline (HR 0.36, 95% CI 0.16C0.83; P?=?0.017) while not modifying the probability of thrombotic events, bleeding, or infections. Table 4 Raw outcomes observed at 30 days. Chi-square and hazard ratios with 95% confidence intervals were reported for adverse events in tocilizumab vs. control groups. Intubation refers only to patients who were not intubated at baseline (n?=?102); bleeding includes clinically relevant events that lead to diagnostic or therapeutic decision; thrombosis includes pulmonary embolism or deep vein thrombosis. survival analysis between day 6 and day 30, following the identical mortality rates between groups until day 5 (when we also observed the nadir of CRP levels in the tocilizumab group), suggested that patients may significantly benefit from JI051 tocilizumab. We should note that these observations follow reports from single-center smaller studies with a shorter observation period and often with a limited use of controls [[7], [8], [9]]. We are aware of the strengths and weaknesses of the present study. Among the former, this is the first controlled study on a large number of patients with COVID-19 either receiving or potentially eligible for tocilizumab based on well-defined criteria for acute respiratory distress syndrome and indicators of inflammation, with a significantly larger number of treated patients and matched controls compared to the JI051 published reports [8,9]. The matching criteria, furthermore, allowed to identify a control group which is comparable to the tocilizumab group and which could have been treated with tocilizumab if this had been widely available. Third, the study was performed in two Centers belonging to the same group, thus allowing a more uniform clinical management of patients in terms of indication for other medical treatments and ventilatory support. Fourth, the baseline differences between the two groups, which may have influenced the results, were either of negligible clinical relevance, as in the case of hemoglobin levels, or failed to prove significant in our univariable analysis, such as symptom duration. In this latter case, we should also note that patients receiving TCZ had a 2-day lag due to the delay in drug supply thus reducing the average differente in disease duration between groups. Among weaknesses, the retrospective design of the study is usually.